Trastuzumab vedotin

DB17391InvestigationalProtein Based Therapies

Trastuzumab vedotin: Overview.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2
Curator reviewed
Code names: MRG002

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Trastuzumab vedotin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.